Last reviewed · How we verify

ALRA — Portfolio Competitive Intelligence Brief

ALRA pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Dimenhydrinate DIMENHYDRINATE marketed dimenhydrinate Histamine H1 receptor Pain 1972-01-01
Azo Gantrisin sulfafurazole marketed Sulfonamide Antimicrobial Endothelin-1 receptor Immunology 1971-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for ALRA:

Cite this brief

Drug Landscape (2026). ALRA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/alra. Accessed 2026-05-15.

Related